DUBLIN — U.S. drugmaker Perrigo agreed Monday to buy Ireland’s Elan for $8.6 billion in a deal that should allow the fast-growing firm to reduce its tax bill and boost its royalty stream.
Perrigo Co. said it would pay $6.25 per share in cash and $10.25 in Perrigo stock for Elan Corp., an 11 percent premium over Elan’s closing price Friday.
Perrigo has been based in the small western Michigan town of Allegan since 1887. Moving its tax residence to Ireland would allow its non-U.S. sales to be taxed at a much lower rate — 12 percent, instead of 35 percent.
Perrigo is already the largest maker of generic drugs for major retail chains in the United States, including Walgreens and Wal-Mart. It has rapidly expanded overseas since 2005.
Guidelines: Please keep your comments smart and civil. Don't attack other readers personally, and keep your language decent. Comments that violate these standards, or our privacy statement or visitor's agreement, are subject to being removed and commenters are subject to being banned. To post comments, you must be a registered user on toledoblade.com. To find out more, please visit the FAQ.